Daily non-political popular news in brief.

Mayo Clinic Cancer Center -- Working on the tough cases

Mayo Clinic Cancer Center, in collaboration with researchers from the University of Iowa, today presented results of a Phase II clinical study indicating that an oral drug, tipifarnib, can stall or reverse disease progression for patients with relapsed aggressive non-Hodgkin lymphoma.

Read more »

Keywords: mayo, clinic, cancer, center, working, tough, cases, case

« Previous | Next »

Similar news on "Mayo Clinic Cancer Center -- Working on the tough cases":

1. Mayo Clinic Cancer Center collaborating to find new tools to fight leukemia
   12-10-2006 · EurekAlert!
   Mayo Clinic Cancer Center, working in collaboration with Ohio State University Comprehensive Cancer Center, presented evidence Sunday that a novel regimen of three chemotherapy drugs, pentostatin, cyclophosphamide and rituximab, resulted in significant clinical response in patients with previously untreated chronic lymphocytic leukemia (CLL).
   Similar news · Read more »
   
2. Mayo Clinic -- Collaborating to move treatment research forward
   12-12-2006 · EurekAlert!
   Novel therapies are greatly improving the long-term outlook for patients with multiple myeloma, say researchers at Mayo Clinic Cancer Center, who have led efforts in testing these treatments and moving them quickly into first-line therapies.
   Similar news · Read more »
   
3. Octogenarians are not too old for cancer surgery
   11-27-2006 · EurekAlert!
   Mayo Clinic Cancer Center researchers have found that a radical prostatectomy can be a viable option for select octogenarian patients. The findings, which run counter the conventional practice of generally avoiding surgeries for individuals over 80 years old solely based on age, are available today in Urology.
   Similar news · Read more »
   
4. Mayo Clinic Cancer Center: Harnessing the measles virus to attack cancer
   10-30-2006 · EurekAlert!
   Mayo Clinic Cancer Center has opened a new clinical study using a vaccine strain of the measles virus to attack recurrent glioblastoma multiforme, a largely untreatable brain tumor.
   Similar news · Read more »
   
5. Mayo Clinic Cancer Center -- individualizing treatment for multiple myeloma patients
   12-10-2006 · EurekAlert!
   Researchers at Mayo Clinic Cancer Center, in cooperation with industry partners, have, for the first time, identified tumor specific alterations in the cellular pathway by which the multiple myeloma drug bortezomib (Velcade) works, and they have identified nine new genetic mutations in cancer cells that should increase a patient's chance of responding to the agent.
   Similar news · Read more »
   
6. Herceptin helps women with multiple chromosomes containing HER2 gene, study finds
   12-14-2007 · EurekAlert!
   The targeted therapy Herceptin helps women with HER2+ type of breast cancer independent of whether patients have extra copies of chromosome 17, home to the HER2 gene which produces the HER2 protein that fuels cancer growth. Prior to this report, there were conflicting opinions about whether that was the case, say Mayo Clinic investigators who presented their findings at the San Antonio Breast Cancer Symposium.
   Similar news · Read more »
   
7. Mayo Clinic study observes normal aging process lowers breast cancer risk
   11-14-2006 · EurekAlert!
   Normal aging of breast tissue lessens breast cancer risk, reports a new study by Mayo Clinic Cancer Center researchers published in the Nov. 15 issue of the Journal of the National Cancer Institute.
   Similar news · Read more »
   
8. Investigating the measles virus as a tool to kill multiple myeloma
   03-05-2007 · EurekAlert!
   Mayo Clinic Cancer Center has opened a new Phase I clinical trial testing an engineered measles virus against multiple myeloma, a cancer of the bone marrow that currently has no cure.
   Similar news · Read more »
   
9. Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma
   04-15-2007 · EurekAlert!
   Mayo Clinic Cancer Center researchers have found that chaetocin, a by-product of a common wood mold, has promise as a new anti-myeloma agent. Results of their study, being presented today at the American Association for Cancer Research annual meeting, show the by-product to be more effective than currently used therapies at killing multiple myeloma cells.
   Similar news · Read more »
   
10. Normal tissue not spared in new forms of breast cancer radiotherapy
    10-30-2007 · EurekAlert!
    A five-day course of radiotherapy to treat breast cancer may, in some cases, expose as much lung and heart tissue to potentially toxic radiation as does the standard six weeks of treatment, say researchers at Mayo Clinic Jacksonville.
    Similar news · Read more »